Julie Zhen Qin Wu

Array ( [id] => 13590033 [patent_doc_number] => 20180346565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => SITE-SPECIFIC ANTIBODY CONJUGATION METHODS AND COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 16/049349 [patent_app_country] => US [patent_app_date] => 2018-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16049349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13565789 [patent_doc_number] => 20180334442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/046578 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440557 [patent_doc_number] => 20180271821 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => Neuroprotection in Demyelinating Diseases [patent_app_type] => utility [patent_app_number] => 15/989683 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4754 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15989683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13400035 [patent_doc_number] => 20180251560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME [patent_app_type] => utility [patent_app_number] => 15/968122 [patent_app_country] => US [patent_app_date] => 2018-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15315 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15968122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283761 [patent_doc_number] => 20200277363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => RECOMBINANT EGFL7, EGFL7 ANTIBODIES, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/607930 [patent_app_country] => US [patent_app_date] => 2018-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16607930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646723 [patent_doc_number] => 20200085891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => ONCOLYTIC VACCINIA VIRUS AND CHECKPOINT INHIBITOR COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/606681 [patent_app_country] => US [patent_app_date] => 2018-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31602 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527289 [patent_doc_number] => 20200055950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => USE OF ANTI-PL2L60 PROTEIN ANTIBODY IN PREPARATION OF ANTI-TUMOR MEDICINE AND METHOD FOR TREATING TUMOR [patent_app_type] => utility [patent_app_number] => 16/346631 [patent_app_country] => US [patent_app_date] => 2018-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13311507 [patent_doc_number] => 20180207290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => ANTI-NKP46 ANTIBODIES, TOXIN CONJUGATES, AND THERAPEUTIC USE OF SAME [patent_app_type] => utility [patent_app_number] => 15/920765 [patent_app_country] => US [patent_app_date] => 2018-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18225 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15920765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13431007 [patent_doc_number] => 20180267046 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => METHODS FOR DIAGNOSING AND TREATING CANCER [patent_app_type] => utility [patent_app_number] => 15/919734 [patent_app_country] => US [patent_app_date] => 2018-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15919734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14729135 [patent_doc_number] => 10383948 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-20 [patent_title] => Anti-cMet antibody drug conjugates and methods for their use [patent_app_type] => utility [patent_app_number] => 15/910788 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 38 [patent_no_of_words] => 54264 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15910788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18180499 [patent_doc_number] => 20230041228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => Small Molecule Inhibition of Micro-RNA-210 Reprograms an Oncogenic Hypoxic Circuit [patent_app_type] => utility [patent_app_number] => 16/486211 [patent_app_country] => US [patent_app_date] => 2018-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16486211 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14519561 [patent_doc_number] => 10337028 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-02 [patent_title] => Nucleic acid-guided nucleases [patent_app_type] => utility [patent_app_number] => 15/896444 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 31 [patent_no_of_words] => 38302 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15896444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14948907 [patent_doc_number] => 10435714 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-08 [patent_title] => Nucleic acid-guided nucleases [patent_app_type] => utility [patent_app_number] => 15/896433 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 31 [patent_no_of_words] => 38390 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15896433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12813304 [patent_doc_number] => 20180162938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-14 [patent_title] => ANTIBODIES SPECIFIC FOR CLAUDIN 6 (CLDN6) [patent_app_type] => utility [patent_app_number] => 15/885454 [patent_app_country] => US [patent_app_date] => 2018-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40197 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15885454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12862342 [patent_doc_number] => 20180179288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => HIGH AFFINITY HUMAN ANTIBODIES TO HUMAN IL-4 RECEPTOR [patent_app_type] => utility [patent_app_number] => 15/874635 [patent_app_country] => US [patent_app_date] => 2018-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8275 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15874635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15086477 [patent_doc_number] => 20190338049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => CONDITIONAL AGONISTS OF IMMUNE RESPONSES [patent_app_type] => utility [patent_app_number] => 16/476614 [patent_app_country] => US [patent_app_date] => 2018-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22022 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16476614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16215147 [patent_doc_number] => 10730945 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-04 [patent_title] => Antibodies reactive with B7-H3 and users thereof [patent_app_type] => utility [patent_app_number] => 15/861966 [patent_app_country] => US [patent_app_date] => 2018-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 85 [patent_no_of_words] => 47396 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15861966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12680803 [patent_doc_number] => 20180118767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => STABLE PANTETHEINE DERIVATIVES FOR THE TREATMENT OF PANTOTHENATE KINASE ASSOCIATED NEURODEGENERATION (PKAN) AND METHODS FOR THE SYNTHESIS OF SUCH COMPOUNDS [patent_app_type] => utility [patent_app_number] => 15/850252 [patent_app_country] => US [patent_app_date] => 2017-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7667 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15850252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012877 [patent_doc_number] => 20200181281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => ANTI-CUB DOMAIN-CONTAINING PROTEIN 1 (CDCP1) ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/469197 [patent_app_country] => US [patent_app_date] => 2017-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 71209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16469197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12862336 [patent_doc_number] => 20180179286 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => MONOCLONAL ANTIBODIES AGAINST HER2 [patent_app_type] => utility [patent_app_number] => 15/832421 [patent_app_country] => US [patent_app_date] => 2017-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15832421 [rel_patent_id] =>[rel_patent_doc_number] =>)